drugset
drugset / Trial / NCT02264093

Effects on the Airway Lumen of Talsaclidine in Combination With Propranolol in Comparison to the Effects of the Monosubstances in Healthy Elderly Male Volunteers

NCT02264093 ↗

Phase 1 Completed 12 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

To investigate the effects on airway lumen of talsaclidine in combination with propranolol and of talsaclidine and propranolol given as monosubstances

Timeline

Start
1999-11
Primary completion
2000-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Propranolol Small molecule 160 mg Oral
Subject Talsaclidine Small molecule 12 mg Oral
Subject Talsaclidine Small molecule 24 mg Oral
Subject Talsaclidine Small molecule 48 mg Oral
Subject Talsaclidine Small molecule 60 mg Oral

Indications

No indication recorded.